Alto Neuroscience/$ANRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alto Neuroscience
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Ticker
$ANRO
Sector
Primary listing
NYSE
Employees
76
Headquarters
Website
ANRO Metrics
BasicAdvanced
$298M
-
-$2.40
-
-
Price and volume
Market cap
$298M
52-week high
$14.15
52-week low
$1.60
Average daily volume
2.3M
Financial strength
Current ratio
18.434
Quick ratio
18.155
Long term debt to equity
19.719
Total debt to equity
20.508
Interest coverage (TTM)
-51.08%
Profitability
EBITDA (TTM)
-69.609
Management effectiveness
Return on assets (TTM)
-24.72%
Return on equity (TTM)
-42.78%
Valuation
Price to book
2.41
Price to tangible book (TTM)
2.41
Price to free cash flow (TTM)
-5.241
Free cash flow yield (TTM)
-19.08%
Free cash flow per share (TTM)
-2.099
Growth
Earnings per share change (TTM)
-37.08%
What the Analysts think about ANRO
Analyst ratings (Buy, Hold, Sell) for Alto Neuroscience stock.
ANRO Financial Performance
Revenues and expenses
ANRO News
AllArticlesVideos
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
Business Wire1 day ago
Alto Neuroscience Announces $50 Million Private Placement Financing
Business Wire1 day ago
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alto Neuroscience stock?
Alto Neuroscience (ANRO) has a market cap of $298M as of October 21, 2025.
What is the P/E ratio for Alto Neuroscience stock?
The price to earnings (P/E) ratio for Alto Neuroscience (ANRO) stock is 0 as of October 21, 2025.
Does Alto Neuroscience stock pay dividends?
No, Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders as of October 21, 2025.
When is the next Alto Neuroscience dividend payment date?
Alto Neuroscience (ANRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alto Neuroscience?
Alto Neuroscience (ANRO) does not currently have a Beta indicator.